In contrast, TRIM22 is upregulated in glioblastoma, where it promotes tumor proliferation [17], while the upregulation of TRIM22 in osteosarcoma suppresses progression by destabilizing NRF2 and activating the ROS/AMPK/mTOR/autophagy signaling pathway [18]. The gene discussed is MTOR; the disease is neoplasm.